Evolent Health, Inc.

NYSE:EVH

Medical - Healthcare Information Services

Healthcare
$3.93 -6.00%

-$0.28 today

Market cap
$442.05M
Beta
0.83
P/E (TTM)
-1.0
EPS (TTM)
-$4.44
52W Low $2.10High $12.07

Volume 3.10M

Average 2.78M

EVH EBITDA Margin

EBITDA as a percentage of revenue.

Evolent Health, Inc.NYSE: EVH

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 2.7%

EBITDA Margin was 2.7% in Q1 FY2026, up 8.7 pp from a year earlier. On a trailing-twelve-month basis it was -16.7%, down 18.0 pp year over year. Over 3 fiscal years it narrowed by 22.5 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of 6.9% for the fiscal year ending Dec 2026, up from -19.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
2.7%+81.0 pp QoQ
Last fiscal yearDec 2025
-19.3%-22.6 pp YoY
LTMMar 2026
-16.7%-18.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+8.7 pp+2.8 pp-5.9 pp
1 year-22.6 pp+26.2 pp+48.8 pp
3 years-22.5 pp+25.0 pp+47.5 pp
5 years+25.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-19.3%
Year-over-year change
-22.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How EVH compares with its peers on the latest reported figures

  • EVH's LTM Mar 2026 EBITDA Margin of -16.7% is the 4th highest of the 9 companies compared; the peer median is -52.6%.
  • Its year-over-year change of -18.0 pp is the 6th highest of 9, against a peer median of -1.9 pp.
  • Over three fiscal years its change of -22.5 pp compares with a peer median of +77.3 pp.
EVH Competitors Peer median
EBITDA Margin for EVH and competitors
Company Period LTM level YoY 3-year change
NUTXNutex Health, Inc.LTM Mar 202633.2% -1.1 pp+212.5 pp
HSTMHealthStream, Inc.LTM Mar 202622.4% +0.1 pp+1.9 pp
AMNAMN Healthcare Services, Inc.LTM Mar 20265.9% +4.5 pp-11.3 pp
EVHEvolent Health, Inc.LTM Mar 2026-16.7% -18.0 pp-22.5 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-40.3% -32.6 pp-27.6 pp
BFLYButterfly Network, Inc.LTM Mar 2026-64.8% -2.6 pp+152.7 pp
MGTXMeiraGTx Holdings plcLTM Mar 2026-120.0% +290.8 pp+619.2 pp
PSNLPersonalis, Inc.LTM Mar 2026-132.6% -47.0 pp—
KURAKura Oncology, Inc.LTM Mar 2026-408.0% -146.3 pp—
REPLReplimune Group, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
Peer median (excluding EVH) -52.6%-1.9 pp+77.3 pp

Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue907.96M1.35B1.96B2.55B1.88B
Cost of Revenue657.55M1.04B1.5B2.19B1.59B
Gross Profit250.41M316.58M460.47M367.35M284.03M
Gross Margin27.6%23.4%23.4%14.4%15.1%
Research & Development027M000
Selling, General & Admin219.5M269.27M358.11M263.05M288.47M
Operating Expenses292.82M312.94M531.68M407.84M288.47M
Depreciation & Amortization60.04M90.25M123.42M123.17M115.85M
EBITDA55.66M43.75M(24.79M)84.85M(361.31M)
EBITDA Margin6.1%3.2%-1.3%3.3%-19.3%
Operating Income(42.41M)3.64M(71.21M)(40.49M)(4.44M)
Operating Margin-4.7%0.3%-3.6%-1.6%-0.2%
Interest Income407K1.37M5.26M5.54M4.19M
Interest Expense25.43M15.57M54.21M24.72M57.47M
Other Income / Expenses12.61M(65.72M)(131.19M)(22.55M)(530.2M)
Income Before Tax(29.8M)(62.08M)(202.41M)(63.04M)(534.64M)
Pre-Tax Margin-3.3%-4.6%-10.3%-2.5%-28.5%
Income Tax Expense483K(43.38M)(89.37M)(1.41M)(126K)
Net Income(37.6M)(19.16M)(113.04M)(61.62M)(534.51M)
Net Margin-4.1%-1.4%-5.8%-2.4%-28.5%
EPS (Basic)(0.36)(0.20)(1.28)(0.81)(5.07)
EPS (Diluted)(0.36)(0.20)(1.28)(0.81)(5.07)
Weighted Avg Shares86.07M93.7M111.25M114.68M114.21M
Weighted Avg Shares (Diluted)86.07M93.7M111.25M114.68M114.21M

Evolent Health, Inc.

NYSE:EVH

Intrinsic Alpha fair value

Locked

Current Price

$3.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.